Monophasic Estrogen-Progestogen Therapy and Sexuality in Postmenopausal Women

Fonseca, Ângela Maggio da; Bagnoli, Vicente Renato; Penteado, Sonia; Paixão, Jucilene Sales da; Cavalcanti, Ana Lucia; Pinotti, José Aristodemo

doi:10.2165/00044011-200727020-00006

Cited by 4 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As such, only research into the efficacy of these specifically recommended forms of estrogen replacement is discussed in the present review. Use of other preparations of topical and systemic hormonal therapies (eg, oral formulations of estrogen supplementation with or without progesterone, tibolone, transdermal E 2 ) to alleviate dyspareunia in samples of postmenopausal women, generally suffering from vaginal atrophy, have also been investigated (eg, [75][76][77][78][79][80]. The majority of published clinical studies examining these alternate forms of hormonal supplementation for the treatment of postmenopausal dyspareunia reported positive results regarding mean improvement.…”

Section: Nonhormonal Vaginal Moisturizermentioning

confidence: 99%

Dyspareunia in Postmenopausal Women: A Critical Review

Kao

Binik²,

Kapuscinski³

et al. 2008

Pain Research and Management

View full text Add to dashboard Cite

Postmenopausal dyspareunia occurring concurrently with vaginal atrophy is strongly associated with a lack of estrogen in the genital tract. However, a significant percentage of postmenopausal women experience dyspareunic pain that is not caused by hypoestrogenism. It is likely that other types of dyspareunia that occur premenopausally are also occurring in postmenopausal women. Research is needed to adequately address this issue. A change in perspective toward a multiaxial pain-focused approach is proposed for future research concerning dyspareunia in postmenopausal women.

show abstract

Section: Nonhormonal Vaginal Moisturizermentioning

confidence: 99%

Dyspareunia in Postmenopausal Women: A Critical Review

Kao

Binik²,

Kapuscinski³

et al. 2008

Pain Research and Management

View full text Add to dashboard Cite

show abstract

Hormone therapy for sexual function in perimenopausal and postmenopausal women

Nastri

Lara

Ferriani

et al. 2013

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

BackgroundThe perimenopausal and postmenopausal periods are associated with many symptoms, including sexual complaints. ObjectivesTo assess the effect of hormone therapy (HT) on sexual function in perimenopausal and postmenopausal women. Search methodsWe searched for articles in the Cochrane Menstrual Disorders and Subfertility Group (MDSG) Specialised Register, CENTRAL, MEDLINE, EMBASE, CINAHL, PsycINFO, LILACS, ClinicalTrials.gov, Current Controlled Trials, WHO International Clinical Trials Registry Platform, ISI Web of Knowledge and OpenGrey. The last search was performed in December 2012. Selection criteriaWe included randomised controlled trials comparing HT to either placebo or no intervention (control). We considered as HT estrogens alone; estrogens in combination with progestogens; synthetic steroids (for example tibolone); or selective estrogen receptor modulators (SERMs) (for example raloxifene, bazedoxifene). Studies of other drugs possibly used in the relief of menopausal symptoms were excluded. We included studies that evaluated sexual function using any validated assessment tool. The primary outcome was a composite score for sexual function and the scores for individual domains (arousal and sexual interest, orgasm, and pain) were secondary outcomes. Studies were selected by two authors independently. Hormone therapy for sexual function in perimenopausal and postmenopausal women (Review)

show abstract